Global Anti-inflammatory Therapeutics Market Size By Type (Anti-Inflammatory Biologicals, NSAIDs), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Anti-inflammatory Therapeutics Market was valued at USD 107.3 billion in 2023 and is projected to reach USD 178.6 billion by 2031, growing at a CAGR of 6.8% from 2023 to 2031. The increasing global burden of chronic inflammatory diseases such as arthritis, inflammatory bowel disease (IBD), and asthma, alongside a growing aging population, is significantly driving market expansion. Rising awareness of early diagnosis and the availability of both biologics and small-molecule drugs are further propelling demand. Additionally, strategic innovations in targeted therapies and biosimilars continue to reshape the competitive landscape.

Drivers:

1. Rising Prevalence of Chronic Inflammatory Disorders:

Conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease are becoming more common globally. This surge in prevalence is a key factor behind the growing demand for anti-inflammatory drugs.

2. Advancements in Biologics and Targeted Therapy:

Biologic drugs, including monoclonal antibodies and interleukin inhibitors, are proving highly effective in managing inflammation, leading to increased patient adoption and physician preference.

3. Growing Geriatric Population:

Elderly individuals are more susceptible to chronic inflammation-related conditions, thereby driving a greater need for long-term therapeutic interventions.

Restraints:

1. High Cost of Biologics:

While highly effective, biologic treatments come with high costs that may limit their accessibility, particularly in low- and middle-income countries.

2. Stringent Regulatory Framework:

Developing and launching anti-inflammatory therapeutics requires extensive clinical trials and regulatory approvals, which can delay market entry and increase R&D costs.

Opportunity:

1. Growth in Biosimilars Market:

The patent expiration of several blockbuster biologics presents a lucrative opportunity for biosimilar manufacturers to offer cost-effective alternatives with comparable efficacy.

2. Expansion in Emerging Economies:

Increasing healthcare infrastructure investment and rising patient awareness in Asia-Pacific and Latin America open new growth avenues for anti-inflammatory drug manufacturers.

Market by System Type Insights:

Based on system type, the biologics segment held the largest market share in 2023, driven by their superior efficacy and targeted approach in treating autoimmune and chronic inflammatory diseases. However, the non-steroidal anti-inflammatory drugs (NSAIDs) segment continues to dominate in terms of volume due to affordability and wide usage for mild to moderate inflammation.

Market by End-use Insights:

In terms of end-use, hospital pharmacies accounted for the highest share in 2023, owing to the preference for biologic infusions and chronic disease management in specialized healthcare settings. Retail pharmacies are expected to grow rapidly, supported by increasing access to over-the-counter NSAIDs and prescription drugs in community settings.

Market by Regional Insights:

North America led the global anti-inflammatory therapeutics market in 2023, supported by a high prevalence of inflammatory diseases, favorable reimbursement policies, and strong R&D infrastructure. Europe follows closely, while the Asia-Pacific region is projected to witness the fastest growth due to increasing healthcare spending, expansion of pharmaceutical companies, and supportive government policies in countries such as India and China.

Competitive Scenario:

Key players in the market include AbbVie Inc., Pfizer Inc., Johnson & Johnson, Amgen Inc., Novartis AG, Bristol-Myers Squibb, Merck & Co., Eli Lilly and Company, F. Hoffmann-La Roche AG, and Takeda Pharmaceutical Company Limited. These companies are actively engaged in strategic collaborations, biosimilar development, and the launch of next-generation anti-inflammatory therapeutics.

Key Developments Include:

In 2024, AbbVie received expanded FDA approval for Rinvoq (upadacitinib) for treating non-radiographic axial spondyloarthritis.

Novartis AG launched a new IL-17A and IL-17F dual inhibitor in Europe in 2023, expanding its immunology pipeline.

In 2025, Johnson & Johnson initiated a strategic biosimilar alliance in India to penetrate emerging markets with cost-effective inflammation treatments.

Scope of Work – Global Anti-inflammatory Therapeutics Market:

Key Market Developments:

2024: AbbVie expanded its immunology portfolio with novel JAK inhibitors gaining wider approvals.

2023: Novartis launched Cosentyx dual-inhibitor biologic in the EU.

2025: Pfizer announced the acquisition of a mid-sized biotech specializing in small-molecule inflammation drugs.

FAQs:

1) What is the current market size of the Global Anti-inflammatory Therapeutics Market?

The market was valued at USD 107.3 billion in 2023.

2) What is the major growth driver of the Global Anti-inflammatory Therapeutics Market?

The increasing prevalence of chronic inflammatory disorders is a major growth driver.

3) Which is the largest region during the forecast period in the Global Anti-inflammatory Therapeutics Market?

North America is projected to remain the largest region due to advanced healthcare infrastructure and high biologic adoption.

4) Which segment accounted for the largest market share in the Global Anti-inflammatory Therapeutics Market?

The biologics segment held the largest share in 2023, owing to high efficacy in autoimmune diseases.

5) Who are the key market players in the Global Anti-inflammatory Therapeutics Market?

Key players include AbbVie Inc., Pfizer Inc., Johnson & Johnson, Amgen Inc., Novartis AG, and Eli Lilly and Company.